• Global Short Bowel Syndrome Treatment Market 
  
  Short bowel syndrome is a collection of issues linked to inadequate nutrition absorption. People who have had at least half of their small intestine removed, and occasionally all or part of their large intestine removed, as well as those who have had considerable damage to their small intestine and poor motility—or movement—within their intestines—are more likely to develop short bowel syndrome.
  Severity of short bowel syndrome might vary based on the small intestine's functioning.
  Global Short Bowel Syndrome market size was valued at USD 944.84 million in 2022 and is expected to expand at a CAGR of 17.53% during the forecast period, reaching USD 2490.37 million by 2028.

Short Bowel Syndrome Treatment Market Mediation
A health care provider may prescribe medications to treat short bowel syndrome including
Antibiotics to prevent bacterial overgrowth

H2 blockers to treat too much gastric acid secretion
Proton pump inhibitors to treat too much gastric acid secretion

Choleretic agents to improve bile flow Prevent liver disease
Bile-salt binders to decrease diarrhea
Anti-secretin agents to reduce gastric acid in the intestine
Growth hormones to improve intestinal absorption
Teduglutide to improve intestinal absorption

Short Bowel Syndrome Treatment Market Dignosed
A health care provider diagnoses short bowel syndrome based on
A medical and family history
A physical exam
Blood tests
Fecal fat tests
An x-ray of the small and large intestines
Upper gastrointestinal (GI) series
Computerized tomography (CT) scan  

Market Dynamics

Drivers
Rising Incidence of Short Bowel Syndrome (SBS)
Increasing prevalence of conditions leading to SBS, such as Crohn’s disease, mesenteric ischemia, and radiation enteritis, is a significant driver. Advances in surgical techniques have also led to an increased number of SBS cases due to improved survival rates in patients undergoing extensive intestinal surgeries.
Advancements in Treatment Options
Development of novel therapies and drug formulations, including growth hormones, glucagon-like peptide-2 (GLP-2) analogs, and nutritional support products, are driving market growth. Innovations in parenteral nutrition and enteral nutrition also contribute to the market expansion.

Restraints

High Cost
High cost associated with SBS treatments, particularly advanced therapies like GLP-2 analogs, presents a significant barrier. The expense of long-term parenteral nutrition also limits patient access, particularly in developing regions with limited healthcare budgets.
Complications and Side Effects
Potential complications and side effects associated with SBS treatments, such as catheter-related infections in parenteral nutrition and adverse reactions to drug therapies, can hinder patient adherence and treatment efficacy.

Opportunities
Emerging Markets
Expansion into emerging markets with growing healthcare infrastructure presents significant opportunities. Increasing investments in healthcare and rising awareness about SBS in these regions can drive market growth.
Development of Oral Therapies
Research and development of oral therapies for SBS offer promising opportunities. Oral therapies can improve patient compliance and quality of life by reducing dependence on parenteral nutrition and its associated risks.

List Of Key Companies Profiled
•    Takeda Pharmaceutical Company Limited (Japan)
•    OxThera (Sweden)
•    Zealand Pharma A/S (Denmark)
•    VectivBio AG (Switzerland)
•    Hanmi Pharm Co., Ltd. (South Korea)
•    9 Meters Biopharma, Inc. (U.S.)
•    Merck KGaA (Germany)
•    Emmaus Medical, Inc. (U.S.)
•    Nestlé Health Science (Switzerland)

Market segmentation
By Drug Type: 
•    GLP-2 
•    Glutamine 
•    Zorbtive 
•    Teduglutide 
•    Others
By Diagnosis: 
•    Physical Exam 
•    Blood Tests 
•    Fecal Fat Tests 
•    Imaging Procedures 
•    Others
By Treatment: 
•    Nutritional Therapy
•    Medications 
•    Surgery 
•    Transplant
By Mode of Administration: 
•    Parenteral Administration and
•    Oral Administration.
By Distribution Channel: 
•    Hospitals 
•    Diagnostics Centers/Multispecialty Clinics 
•    Hospital/Retail Pharmacies 
•    Others
By Geography: 
•    North America, 
•    Europe 
•    Asia-Pacific 
•    RoW

Acquisitions/Product Launches
In May 17, 2019 Takeda Pharmaceuticals, U.S.A., Inc. ("Takeda"), announced today that the U.S. Food and Drug Administration (FDA) approved extending the indication of GATTEX® (teduglutide) for injection to pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who need additional nutrition or fluids from intravenous (IV) feeding (parenteral support)
In February 10, 2020 Scottish Medicines Consortium accepts Revestive® ▼ (teduglutide) for use in NHS Scotland for adult patients with short bowel syndrome, after previously issuing advice restricting its use to pediatric patients only (aged 1-17 years) in 2018.

Key Industry Development

June 2022 – 9 Meters Biopharma, Inc. announced the positive results of the phase 2 clinical study of Vurolenatide in treating this syndrome.
 August 2021 – Zealand Pharma A/S announced the dose administration of Glepaglutide to the first patient in the phase 3b clinical trial for the treatment of short bowel syndrome.
 April 2021 – Hanmi Pharm.Co., Ltd. announced that it received fast-track designation by the U.S. FDA for its HM15912(GLP-2 Analog) used for treating this syndrome.
November 2018 – The U.S. FDA accepted Shire plc’s application for GATTEX to extend its use on pediatric patients aged 1-17 years suffering from this condition.